| Literature DB >> 36192686 |
Cen Shi1,2, Yixing Yu1,2, Jiulong Yan1,2, Chunhong Hu3,4.
Abstract
BACKGROUND: The histological differentiation grades of gastric cancer (GC) are closely related to treatment choices and prognostic evaluation. Radiomics from dual-energy spectral CT (DESCT) derived iodine-based material decomposition (IMD) images may have the potential to reflect histological grades.Entities:
Keywords: Dual-energy spectral CT; Gastric cancer; Histologic grade; Iodine-based material decomposition images; Radiomics
Mesh:
Substances:
Year: 2022 PMID: 36192686 PMCID: PMC9528064 DOI: 10.1186/s12880-022-00899-y
Source DB: PubMed Journal: BMC Med Imaging ISSN: 1471-2342 Impact factor: 2.795
Fig. 1Flowchart of patient enrollment
Fig. 2Delineation of the volume of interest (VOI). A gastric cancer located in the cardia was shown in a axial portal phase images; b iodine-based MD images; c coronal multiplanar reconstruction images. d Three-dimensional VOI of the tumor was displayed
Fig. 3Flowchart of our study
Clinical characteristics of the patients in training and testing cohorts
| Characteristics | Training set (n = 72) | Testing set (n = 31) | ||||
|---|---|---|---|---|---|---|
| Low-grade | High-grade | P value | Low-grade | High-grade | P value | |
| Age | 70.29 ± 8.19 | 66.43 ± 11.12 | 0.119 | 65.33 ± 11.48 | 64.11 ± 11.72 | 0.777 |
| Gender | 0.714 | 0.178 | ||||
| Female | 9 | 16 | 1 | 7 | ||
| Male | 19 | 28 | 11 | 12 | ||
| Tumor long axis | 4.53 ± 2.73 | 5.39 ± 2.85 | 0.209 | 3.60 ± 1.71 | 5.66 ± 3.55 | 0.039 |
| pT stage | 0.005 | 0.025 | ||||
| T1 | 5 | 0 | 5 | 0 | ||
| T2 | 4 | 5 | 0 | 1 | ||
| T3 | 5 | 4 | 2 | 4 | ||
| T4 | 14 | 35 | 5 | 14 | ||
| pN stage | < 0.001 | < 0.001 | ||||
| N0 | 11 | 6 | 6 | 1 | ||
| N1 | 5 | 2 | 2 | 1 | ||
| N2 | 7 | 17 | 3 | 4 | ||
| N3 | 5 | 29 | 1 | 13 | ||
| Location | 0.115 | 0.278 | ||||
| Upper 1/3 | 10 | 10 | 3 | 4 | ||
| Middle 1/3 | 10 | 14 | 5 | 5 | ||
| Lower 1/3 | 7 | 16 | 4 | 7 | ||
| Multiple | 1 | 4 | 0 | 3 | ||
| AFP | 1.000 | 1.000 | ||||
| Normal | 26 | 41 | 12 | 19 | ||
| Abnormal | 2 | 3 | 0 | 0 | ||
| CEA | 0.147 | 1.000 | ||||
| Normal | 23 | 42 | 12 | 19 | ||
| Abnormal | 5 | 2 | 0 | 0 | ||
| CA125 | 0.884 | 0.510 | ||||
| Normal | 25 | 41 | 12 | 17 | ||
| Abnormal | 3 | 3 | 0 | 2 | ||
| CA19-9 | 0.553 | 0.409 | ||||
| Normal | 22 | 37 | 7 | 15 | ||
| Abnormal | 6 | 7 | 5 | 4 | ||
| CA72-4 | 0.620 | 0.510 | ||||
| Normal | 23 | 34 | 12 | 17 | ||
| Abnormal | 5 | 10 | 0 | 2 | ||
| CA153 | 1.000 | 1.000 | ||||
| Normal | 27 | 43 | 12 | 19 | ||
| Abnormal | 1 | 1 | 0 | 0 | ||
Diagnostic performance of models in training and testing cohorts
| AUC (95% CI) | ACC | SEN | SPE | PPV | NPV | |
|---|---|---|---|---|---|---|
| Model-Clinical | ||||||
| Training | 0.674 (0.543–0.804) | 0.694 | 0.795 | 0.536 | 0.729 | 0.625 |
| Testing | 0.847 (0.612–0.950) | 0.710 | 0.579 | 0.917 | 0.917 | 0.579 |
| Model-CP | ||||||
| Training | 0.802 (0.693–0.911) | 0.792 | 0.818 | 0.750 | 0.837 | 0.724 |
| Testing | 0.781 (0.612–0.950) | 0.742 | 0.737 | 0.750 | 0.824 | 0.643 |
| Model-IMD | ||||||
| Training | 0.871 (0.793–0.950) | 0.792 | 0.818 | 0.750 | 0.837 | 0.724 |
| Testing | 0.759 (0.582–0.936) | 0.774 | 0.790 | 0.750 | 0.833 | 0.692 |
| Model-CP–IMD | ||||||
| Training | 0.900 (0.830–0.971) | 0.861 | 0.818 | 0.927 | 0.947 | 0.765 |
| Testing | 0.851 (0.711–0.991) | 0.839 | 0.842 | 0.833 | 0.889 | 0.769 |
| Model-Combine | ||||||
| Training | 0.910 (0.837–0.983) | 0.875 | 0.955 | 0.750 | 0.857 | 0.913 |
| Testing | 0.912 (0.778–1.000) | 0.936 | 0.747 | 0.917 | 0.974 | 0.917 |
AUC area under the receiver operating curve, 95% CI 95% confidence interval, ACC accuracy, SEN sensitivity, SPE specificity, PPV positive predictive value, NPV negative predictive value
Fig. 4Features contained in models and their weights. a Model-CP; b model-IMD; c model-CP–IMD; d model-Combine
Fig. 5ROC curves of the models in a training set and b testing set
Fig. 6DeLong’s test results in a training set and b testing set
Fig. 7Calibration curves of model-Combine in a training cohort and b testing cohort
Fig. 8Decision curve analysis for all models in the whole dataset. A larger area under the decision curve indicates a better clinical utility. Model-Combine added more net benefit than model-CP at the range of 0.1–0.9 and model-CP–IMD added more net benefit than model-CP at the range of 0.3–1.0. In comparison to model-Clinical, model-Combine owned a larger net benefit at a range threshold probability of 0.05–0.95